Vastuskiri

Dear Dr. Podolak,

You can pay the invoice sent to you by the Health Board for the current soon-to-be-submitted study application regardless of when the study will be actually submitted (be it December, January or even February). We will handle the payment transfer from the Health Board to the State Agency of Medicines ourselves. Be aware that we are expecting the fee to be paid in 40 days since issuing the invoice (issued November 19th, 2024) – therefore, the payment should be made December 28th, 2024 at the latest.

In case there is another application for another study foreseen in the future (i.e some time next year), all the procedures regarding applying for a medical device study still remain the same– the sponsor will define the type of study they are applying for and we will send the invoice to the sponsor for the CA (State Agency of Medicines) fee. Fees will remain the same. The only thing that will change is the organisation the Estonian Medical Devices Department operates under – until December 31st, we are operating under the Health Board, starting from January 1st, 2025, our work continues under the State Agency of Medicines.

Happy holidays,  

Dear Ms Merili Saar-Abroi,

May I have one more question? I’d like to check how this transfer eventually impact the payment process. Are we still supposed to write an email with an invoice request and then proceed with paying the CA fee and state fee (separately) just using new CA’s details? I’d appreciate your confirmation.

Dear Dr. Podolak,

Yes, all the procedures remain the same and are not affected by our transfer to State Agency of Medicines.

All the best,

Dear Ms Merili Saar-Abroi,

Thank you very much for your prompt response and this explanation. I understand that both requirements and timelines remain the same after this transfer, correct? I would highly appreciate your confirmation.

Dear Dr. Podolak

According to the IVDR article 66, we are required to notify the sponsor as to whether the performance study falls within the scope of the IVDR and as to whether the application dossier is complete within 10 days of receiving the application. In case you apply December 17th at the latest, we will validate the application or ask for additional comments regarding your application December 27th at the latest. In 2025, we will be available again starting from January 6th. As we are transferring to the State Agency of Medicines starting from January 1st, 2025, our e-mail address from then on will be [email protected]

All of the medical devices department and it’s employees will be transferred from the Health Board to the State Agency of Medicines in full, therefore, the application will be transferred to the State Agency of Medicine automatically. No adjustments from the sponsor regarding our transfer are foreseen.

All fees remain valid and will be transferred internally from the Health Board and the State Agency of Medicines. The sponsor will not have any obligations regarding the fees already paid.

All the best,

Dear Sirs,

I would like to ask if there is any break planned for the Christmas period. If we apply before Christmas, is it likely that we will receive validation comments by the end of this year?

In addition, I would like to make sure how the evaluation of applications will look like due to the change in the authority for medical device testing? Will applications submitted in December still be evaluated by the Health Board, or will they be transferred to the State Agency of Medicines with the new year?

I would also like to ask if we do not manage to submit the application in December and have to submit it to the State Agency of Medicines in January, does the fee we have already submitted remain valid? Would we have to start some kind of procedure to redirect the funds or refund and make the payment again to the new competent authority?

________________________________________
IMPORTANT - PLEASE READ: This electronic message, including its attachments, is CONFIDENTIAL and may contain PROPRIETARY or LEGALLY PRIVILEGED or PROTECTED information and is intended for the authorized recipient of the sender. If you are not the intended recipient, you are hereby notified that any use, disclosure, copying, or distribution of this message or any of the information included in it is unauthorized and strictly prohibited. If you have received this message in error, please immediately notify the sender by reply e-mail and permanently delete this message and its attachments, along with any copies thereof, from all locations received (e.g., computer, mobile device, etc.). To the extent permitted by law, we may monitor electronic communications for the purposes of ensuring compliance with our legal and regulatory obligations and internal policies. We may also collect email traffic headers for analyzing patterns of network traffic and managing client relationships. For further information see our privacy-policy. Thank you.